Abstract:Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal disorder caused by the deficiency of arylsulfatase A (ASA), resulting in impaired degradation of sulfatide, an essential sphingolipid of myelin. The clinical manifestations of MLD are characterized by progressive demyelination and subsequent neurological symptoms resulting in severe debilitation. The availability of therapeutic options for treating MLD is limited but expanding with a number of early stage clinical trials already in progress. In the development of therapeutic approaches for MLD, scientists have been facing a number of challenges including blood-brain barrier (BBB) penetration, safety issues concerning therapies targeting the central nervous system, uncertainty regarding the ideal timing for intervention in the disease course, and the lack of more in-depth understanding of the molecular pathogenesis of MLD. Here, we discuss the current status of the different approaches to developing therapies for MLD. Hematopoietic stem cell transplantation has been used to treat MLD patients, utilizing both umbilical cord blood and bone marrow sources. Intrathecal enzyme replacement therapy and gene therapies, administered locally into the brain or by generating genetically modified hematopoietic stem cells, are emerging as novel strategies. In pre-clinical studies, different cell delivery systems including microencapsulated cells or selectively neural cells have shown encouraging results. Small molecules that are more likely to cross the BBB can be used as enzyme enhancers of diverse ASA mutants, either as pharmacological chaperones, or proteostasis regulators. Specific small molecules may also be used to reduce the biosynthesis of sulfatides, or target different affected downstream pathways secondary to the primary ASA deficiency. Given the progressive neurodegenerative aspects of MLD, also seen in other lysosomal diseases, current and future therapeutic strategies will be complementary, whether used in combination or separately at specific stages of the disease course, to produce better outcomes for patients afflicted with this devastating inherited disorder.

Exploring the effect of disease causing mutations in metal binding sites of human ARSA in metachromatic leukodystrophy

Identification of Novel ARSA Mutations in Chinese Patients with Metachromatic Leukodystrophy.

Biochemical and molecular analysis of pediatric patients with metachromatic leukodystrophy in South China: functional characterization of five novel ARSA variants

Identification of two novel arylsulfatase A mutations with a polymorphism as a cause of metachromatic leukodystrophy

A Novel Arsa Gene Mutation C.302delg In A Chinese Patient With Metachromatic Leukodystrophy

[Analysis of ARSA Mutations in a Chinese Family with Metachromatic Leukodystrophy].

Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novel ARSA alleles

Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T

Developing therapeutic approaches for metachromatic leukodystrophy

Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype

[Analysis of ARSA gene variant in an infant with late infantile metachromatic leukodystrophy].

A systematic review on the birth prevalence of metachromatic leukodystrophy

Arylsulftase A gene mutations in 8 patients with metachromatic leukodystrophy

Complete Correction of Brain and Spinal Cord Pathology in Metachromatic Leukodystrophy Mice

Effects of Sulfatide Accumulation on Peripheral Nerves in Metachromatic Leukodystrophy (P3-5.001)

Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy

Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy

Delay of myelin formation in arylsulphatase A-deficient mice

Allogeneic Hematopoietic Cell Transplantation for Adult Metachromatic Leukodystrophy (MLD): A Case Series

Metachromatic leukodystrophy: consequences of sulphatide accumulation

Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective